DCGI Approval for Zydus Cadila’s ZyCoV-D : DNA-based vaccine for COVID-19

DCGI Approval for Zydus Cadila’s ZyCoV-D : DNA-based vaccine for COVID-19

India has approved a Zydus Cadila vaccine, ZyCoV-D, that can be given to all persons 12 years and older, including children. A statement has been issued by the Ministry of Science and Technology that Zydus Cadila has been approved by DCGI for urgent use with ZyCoV-D. “These were the first vaccines to be administered to all people including children and adults aged 12 and over in the world, indigenously-developed DNA-based vaccine COVID-19.” said the ministry.

Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world

|amp|

Zydus Cadila is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.

Zydus’ global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.

Previously, the Central Drug Agency of India expert panel recommended that the three-dose “ZyCoV-D” vaccine from Zydus Cadila is taken in an emergency way.

Zydus Cadila

The Subject Expert Commission on Covid-19 of the Central Drug Standard Control Organization (CDSCO) on Thursday discussed the Zydus Cadila application and approved the emergency use of its coronavirus vaccine with a dose of three doses. recommended.

The pharmaceutical company based in Ahmedabad requested DCGI for an emergency vaccine authorisation on 1 July. The enterprise said that the largest clinical trial in over 50 centres has been conducted so far.

Now after approval, this has been developed by an Indian company and is now the sixth antibody in the country to be used, the first anti-coronavirus DNA vaccine in the world. Earlier, there have been useful activities such as Kovishield of Serum Institute, Bharat Biotech Covaxin, Sputnik V of Russia, Moderna and Johnson and Johnson of America.

Be the first to comment

Leave a Reply

Your email address will not be published.


*